Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 May 2022, 20:05.
Pascal Deschatelets - 21 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 21 Apr 2022
- Net transaction value
- -$167,040
- SEC form
- 4
- Accepted by SEC
- 02 May 2022, 20:05:25 UTC
- Prior SEC filing
- 14 Feb 2022
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 02 May 2022.
Change
- Previous filing in this sequence was filed on 14 Feb 2022.
- Current net transaction value: -$167,040.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -1,875
- Change %
- -0.21%
- Price
- $0.000000
- Shares after
- 891,775
- Date
- 21 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Options Exercise
- Transaction value
- $10,680
- Shares
- +4,000
- Change %
- +0.45%
- Price
- $2.67*
- Shares after
- 895,775
- Date
- 29 Apr 2022
- Ownership
- Direct
- Footnotes
- F2
APLS
transaction
Common Stock
Sale
- Transaction value
- $177,720
- Shares
- -4,000
- Change %
- -0.45%
- Price
- $44.43
- Shares after
- 891,775
- Date
- 29 Apr 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -11,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,250
- Exercise price
- $44.90
- Footnotes
- F3, F4
APLS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,000
- Change %
- -1.1%
- Price
- $0.000000
- Shares after
- 364,999
- Date
- 29 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- $2.67
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
Footnote F2
This is a scheduled exercise and sale from a 10B5-1 trading plan.
Footnote F3
This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
Footnote F4
This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
Footnote F5
This stock option was granted on 12/5/2013 and is fully vested.